CX3CR1 and diffuse large B-cell lymphoma: In this prospective cohort study involving 89 DLBCL patients, we investigated the impact of PB- and BM-CD11b+CX3CR1+ monocytes on survival outcomes in patients with newly diagnosed DLBCL treated with R-CHOP immunochemotherapy.